Nektar/BMS’s IL-2 Inhibitor Melanoma Failure Leaves Room For Other Contenders
Nektar is hoping the combination of bempegaldesleukin and Opdivo could have better chances in kidney and bladder cancers, but analysts aren’t sure and see other IL-2 therapeutics as having better prospects.
You may also be interested in...
After two failures in a row from Roche, the TIGIT hypothesis is looking shaky, but it is too early to write off the class yet.
Nektar/BMS Deal Takes Second Gut Punch As IL-2/PD-1 Combo Goes Down In Flames
In this week's podcast edition of Five Must-Know Things: clinical setbacks in melanoma and prostate cancer; Chinese pharma firms face US listing pressures; Eisai hands Aduhelm to Biogen; and Scrip Asks what 2022 holds for digital and telehealth.